TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects
Authors
Keywords
Cancer treatment, Toxicity, Hepatocytes, Cytokines, Mouse models, Transcription factors, Neutrophils, Toll-like receptors
Journal
PLoS One
Volume 15, Issue 2, Pages e0227940
Publisher
Public Library of Science (PLoS)
Online
2020-02-07
DOI
10.1371/journal.pone.0227940
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mitochondrial dysfunction and endoplasmic reticulum stress involved in oocyte aging: an analysis using single-cell RNA-sequencing of mouse oocytes
- (2019) Tao Zhang et al. Journal of Ovarian Research
- A New Venue of TNF Targeting
- (2018) Sophie Steeland et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Intrinsic mechanisms of neuronal axon regeneration
- (2018) Marcus Mahar et al. NATURE REVIEWS NEUROSCIENCE
- Exotoxins and endotoxins: Inducers of inflammatory cytokines
- (2018) Jean-Marc Cavaillon TOXICON
- Unleashing endogenous TNF-alpha as a cancer immunotherapeutic
- (2018) Steven F. Josephs et al. Journal of Translational Medicine
- Mitigation of Radiation-Induced Epithelial Damage by the TLR5 Agonist Entolimod in a Mouse Model of Fractionated Head and Neck Irradiation
- (2017) Ilia A. Toshkov et al. RADIATION RESEARCH
- Therapeutic benefit of Salmonella attributed to LPS and TNF-α is exhaustible and dictated by tumor susceptibility
- (2017) Dino Kocijancic et al. Oncotarget
- Endothelial Regulator of Calcineurin 1 Promotes Barrier Integrity and Modulates Histamine-Induced Barrier Dysfunction in Anaphylaxis
- (2017) Constanza Ballesteros-Martinez et al. Frontiers in Immunology
- The immune system's role in sepsis progression, resolution, and long-term outcome
- (2016) Matthew J. Delano et al. IMMUNOLOGICAL REVIEWS
- Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+T-cell axis
- (2016) Craig M. Brackett et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Combined treatment with MSC transplantation and neutrophil depletion ameliorates D-GalN/LPS-induced acute liver failure in rats
- (2016) Xin Zhao et al. Clinics and Research in Hepatology and Gastroenterology
- Microbially Driven TLR5-Dependent Signaling Governs Distal Malignant Progression through Tumor-Promoting Inflammation
- (2015) Melanie R. Rutkowski et al. CANCER CELL
- Systemic use of tumor necrosis factor alpha as an anticancer agent
- (2015) Nicholas J. Roberts et al. Oncotarget
- Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice
- (2015) Bojidar M. Kojouharov et al. Oncotarget
- Isolated hepatic perfusion: Principles and results
- (2014) O. Facy et al. Journal of Visceral Surgery
- CXCL1 expression in human decidua in vitro is mediated via the MAPK signalling cascade
- (2013) Dunja Maria Baston-Büst et al. CYTOKINE
- Differential Roles of CXCL2 and CXCL3 and Their Receptors in Regulating Normal and Asthmatic Airway Smooth Muscle Cell Migration
- (2013) L. A. Al-Alwan et al. JOURNAL OF IMMUNOLOGY
- Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist
- (2013) L. G. Burdelya et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation
- (2013) K Kono et al. Cell Death & Disease
- Structural Basis of TLR5-Flagellin Recognition and Signaling
- (2012) S.-i. Yoon et al. SCIENCE
- The inflammatory response in sepsis
- (2012) Markus Bosmann et al. TRENDS IN IMMUNOLOGY
- Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey
- (2011) B. B. Aggarwal et al. BLOOD
- Activation of Toll-like Receptor 5 on Breast Cancer Cells by Flagellin Suppresses Cell Proliferation and Tumor Growth
- (2011) Z. Cai et al. CANCER RESEARCH
- A TLR5 Agonist Inhibits Acute Renal Ischemic Failure
- (2011) N. Fukuzawa et al. JOURNAL OF IMMUNOLOGY
- TLR5 activation induces secretory interleukin-1 receptor antagonist (sIL-1Ra) and reduces inflammasome-associated tissue damage
- (2010) F A Carvalho et al. Mucosal Immunology
- Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice
- (2008) Alexander Riad et al. EUROPEAN JOURNAL OF HEART FAILURE
- Toll-Like Receptor 5-Deficient Mice Have Dysregulated Intestinal Gene Expression and Nonspecific Resistance to Salmonella-Induced Typhoid-Like Disease
- (2008) M. Vijay-Kumar et al. INFECTION AND IMMUNITY
- Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: Long-term results on efficacy and limb salvage in a selected group of patients
- (2008) Stéphane Cherix et al. JOURNAL OF SURGICAL ONCOLOGY
- An Agonist of Toll-Like Receptor 5 Has Radioprotective Activity in Mouse and Primate Models
- (2008) L. G. Burdelya et al. SCIENCE
- Development of Isolated Hepatic Perfusion for Patients Who Have Unresectable Hepatic Malignancies
- (2008) Adriana Jones et al. Surgical Oncology Clinics of North America
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now